Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide plus low glycaemic index lifestyle vs placebo for hypothalamic obesity after childhood cranial cancer therapy
2006-000492-16Phase 2Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- May 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hypothalamic obesity (HO) comparing Somatuline Autogel + LGIL with Placebo + LGIL (2 arms). Primary endpoint: Proportion of children with stable weight over 6 months. Started May 2006; status: terminated.
02
Drugs
lanreotide
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on 2006-000492-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000492-16.